|Generic name||Axicabtagene ciloleucel|
|Brand name(s), other common name(s)||YescartaTM|
|How the drug is given||Intravenous infusion|
Indications and Usage
Axicabtagene ciloleucel is a CD19-directed genetically modified autologous T cell immunotherapy FDA approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.
Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.
Side effects needing medical attention
Cytokine release syndrome, fever, low blood pressure (hypotension), encephalopathy, fast or irregular heartbeat (tachycardia), fatigue, headache, decreased appetite, chills, diarrhea, febrile neutropenia, infections-pathogen unspecified, nausea, not enough blood in the arteries (hypoxia), tremor, cough, vomiting, dizziness, constipation, and cardiac arrhythmias.
Cytokine release syndrome and neurological toxicities
See full prescribing information for complete boxed warning.
- Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving Yescarta. Do not administer Yescarta to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids.
- Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving Yescarta, including concurrently with CRS or after CRS resolution. Monitor for neurologic toxicities after treatment with Yescarta. Provide supportive care and/or corticosteroids as needed.
- Yescarta is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Yescarta REMS